BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 23528367)

  • 1. The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.
    Crimins JL; Pooler A; Polydoro M; Luebke JI; Spires-Jones TL
    Ageing Res Rev; 2013 Jun; 12(3):757-63. PubMed ID: 23528367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intersection of amyloid beta and tau at synapses in Alzheimer's disease.
    Spires-Jones TL; Hyman BT
    Neuron; 2014 May; 82(4):756-71. PubMed ID: 24853936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A role for tau at the synapse in Alzheimer's disease pathogenesis.
    Pooler AM; Noble W; Hanger DP
    Neuropharmacology; 2014 Jan; 76 Pt A():1-8. PubMed ID: 24076336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer's Disease.
    Yin X; Qiu Y; Zhao C; Zhou Z; Bao J; Qian W
    Med Sci Monit; 2021 Sep; 27():e933084. PubMed ID: 34471085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Tau in Alzheimer's Disease.
    Ittner A; Ittner LM
    Neuron; 2018 Jul; 99(1):13-27. PubMed ID: 30001506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spines, plasticity, and cognition in Alzheimer's model mice.
    Spires-Jones T; Knafo S
    Neural Plast; 2012; 2012():319836. PubMed ID: 22203915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau acts as a mediator for Alzheimer's disease-related synaptic deficits.
    Liao D; Miller EC; Teravskis PJ
    Eur J Neurosci; 2014 Apr; 39(7):1202-13. PubMed ID: 24712999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses.
    Willén K; Sroka A; Takahashi RH; Gouras GK
    J Alzheimers Dis; 2017; 60(2):511-524. PubMed ID: 28869466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
    Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.
    Li K; Wei Q; Liu FF; Hu F; Xie AJ; Zhu LQ; Liu D
    Mol Neurobiol; 2018 Apr; 55(4):3021-3032. PubMed ID: 28456942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiation
    Ondrejcak T; Klyubin I; Hu NW; O'Malley TT; Corbett GT; Winters R; Perkinton MS; Billinton A; Prenderville JA; Walsh DM; Rowan MJ
    J Neurosci; 2023 Aug; 43(32):5870-5879. PubMed ID: 37491315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid.
    Nimmrich V; Ebert U
    Rev Neurosci; 2009; 20(1):1-12. PubMed ID: 19526730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives.
    Lista S; Santos-Lozano A; Emanuele E; Mercuri NB; Gabelle A; López-Ortiz S; Martín-Hernández J; Maisto N; Imbimbo C; Caraci F; Imbimbo BP; Zetterberg H; Nisticò R
    Mol Psychiatry; 2024 Mar; 29(3):847-857. PubMed ID: 38228892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating small extracellular vesicles in Alzheimer's disease: a case-control study of neuro-inflammation and synaptic dysfunction.
    Singh R; Rai S; Bharti PS; Zehra S; Gorai PK; Modi GP; Rani N; Dev K; Inampudi KK; Y VV; Chatterjee P; Nikolajeff F; Kumar S
    BMC Med; 2024 Jun; 22(1):254. PubMed ID: 38902659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.